Send to:

Choose Destination
See comment in PubMed Commons below
Nihon Rinsho. 2014 Jan;72(1):29-34.

[Perspective of personalized (precise) cancer therapy based on predictive biomarkers].

[Article in Japanese]

Author information

  • 1Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East.


The epidermal growth factor receptor (EGFR), a receptor tyrosine kinase, triggers a downstream signaling cascade through areas such as the RAS-RAF-MAPK, PI3K-AKT and JAK-STAT pathways, which are involved in cell proliferation, dedifferentiation and inhibition of apoptosis. Two anti-EGFR monoclonal antibodies, cetuximab and panitumumab, are currently available for the treatment of metastatic colorectal cancer. KRAS is a validated predictive biomarker for anti-EGFR therapy and tumor KRAS status should be determined whenever anti-EGFR therapy is considered in the treatment of metastatic colorectal cancer. On the other hand, the promising biomarkers such as NRAS, BRAF and PIK3CA for anti-EGFR monoclonal antibody, and pVEGF-A for bevacizumab have been reported. We review the biomarkers associated with personalized therapy in colorectal cancer.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk